Ron Alfa, Co-Foundar/CEO of NEOTIK, shared a post on LinkedIn:

“Today NOETIK and Agenus announced an exciting collaboration to deploy our virtual cell foundation models in the context of an active clinical program for the first time.

We know that Noetik models can learn patient biology, and predict which patients will respond to approved drugs such as anti-PD1. Together with Agenus, we’ll test capabilities of our models to enrich responders for the BOT/BAL program.

Predicting clinical success is the most critical bottleneck in bringing new medicines to patients. Today, we’re directing the most advanced foundation models in translational medicine at this challenging problem.”

Learn More.

Read Further.

Agenus Presented New Translational Data at the ASCO 2025

Agenus Names Leading GI Oncologist Dr. Richard Goldberg as Chief Development Officer

Agenus Bets Big on Botensilimab

agenus botensilimab fda

Ron Alfa: Noetik and Agenus Announced an Exciting Collaboration to Deploy Foundation Models to Predict Immunotherapy Response

“Today NOETIK and Agenus announced an exciting collaboration to deploy our virtual cell foundation models in the context of an active clinical program for the first time.

We know that Noetik models can learn patient biology, and predict which patients will respond to approved drugs such as anti-PD1. Together with Agenus, we’ll test capabilities of our models to enrich responders for the BOT/BAL program.

Predicting clinical success is the most critical bottleneck in bringing new medicines to patients. Today, we’re directing the most advanced foundation models in translational medicine at this challenging problem.”